AstraZeneca’s First Direct-to-Patient Program for ARIMIDEX® (anastrozole) Tablets
AstraZeneca today announced its first-ever, direct-to-patient program offering patients with a valid prescription for ARIMIDEX or the generic anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.
“ARIMIDEX Direct marks a first for AstraZeneca,” said Steve Davis, Executive Director, Foundation Brands, AstraZeneca. “We believe it is also the first time eligible patients have a nationwide direct-to-patient option.”
Since a generic option has become available in 2010, many health care plans can no longer cover ARIMIDEX due to their generics first policies. Patients started calling the Information Center asking how they could get the brand ARIMIDEX more affordably. ARIMIDEX Direct is an important new way for AstraZeneca to help meet customer needs for patients who elect to receive and pay for the brand ARIMIDEX on their own.
For more information on how to enroll in the program, click on the attached press release.
ARIMIDEX is a registered trademark of the AstraZeneca group of companies.
-By Anna Padula, Senior Manager for Brand Corporate Affairs at AstraZeneca